Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

BMY is banking on new drugs to offset generic competition for older drugs. However, this might not be enough as the outlook ...

NICE has issued a final “no” to Bristol-Myers Squibb’s oral MS drug Zeposia (ozanimod), in a decision that prevents access for patients in England and Wales.

The oral S1P1 and S1P5 receptor agonist drug – now given the trade name Zeposia – was billed as one of the top 2020 drug launches to watch by Clarivate last month, before the COVID-19 outbreak ...

Other drugs like Zeposia and Krazati should also contribute to top-line growth. BMY recently won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

After hours: March 13 at 7:56:14 PM EDT Loading Chart for BMY ...

After hours: 11 March at 19:56:05 GMT-4 Loading Chart for BMY ...

WAUSEON – The Fulton County commissioners received an update from the County Employee Benefit Consortium of Ohio (CEBCO) during their regular session Tuesday. Melissa Bodey of CEBCO presented a review ...